Crispr Therapeutics AG (NASDAQ:CRSP) President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Crispr Therapeutics stock traded up $0.97 during midday trading on Monday, hitting $66.33. 920,983 shares of the company were exchanged, compared to its average volume of 713,132. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics AG has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The company’s fifty day moving average price is $58.93 and its 200-day moving average price is $48.44. The company has a market cap of $3.61 billion, a PE ratio of -19.28 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. On average, analysts expect that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the business. BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $39,000. Balyasny Asset Management LLC bought a new stake in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $5,165,000. BNP Paribas Arbitrage SA bought a new stake in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $41,000. Bank of New York Mellon Corp increased its holdings in shares of Crispr Therapeutics by 116.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC increased its holdings in shares of Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the last quarter. Institutional investors own 49.82% of the company’s stock.
CRSP has been the subject of a number of research analyst reports. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Goldman Sachs Group lifted their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. BidaskClub cut Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $69.54.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What does relative strength index mean?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.